Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (Diluted Average): 2021-2024

Historic Shares Outstanding (Diluted Average) for Heron Therapeutics (HRTX) over the last 4 years, with Dec 2024 value amounting to $152.4 million.

  • Heron Therapeutics' Shares Outstanding (Diluted Average) rose 11.46% to $170.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.3 million, marking a year-over-year increase of 11.46%. This contributed to the annual value of $152.4 million for FY2024, which is 10.36% up from last year.
  • Heron Therapeutics' Shares Outstanding (Diluted Average) amounted to $152.4 million in FY2024, which was up 10.36% from $138.1 million recorded in FY2023.
  • Over the past 5 years, Heron Therapeutics' Shares Outstanding (Diluted Average) peaked at $152.4 million during FY2024, and registered a low of $98,471 during FY2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $138.1 million (2023), whereas its average is $133.2 million.
  • Data for Heron Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 110,466.56% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Heron Therapeutics' Shares Outstanding (Diluted Average) stood at $98,471 in 2021, then skyrocketed by 110,466.56% to $108.9 million in 2022, then grew by 26.87% to $138.1 million in 2023, then rose by 10.36% to $152.4 million in 2024.